Compare Davita Inc (DVA) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Visa Inc — how do they compare? Davita Inc trades at $232 (market cap $15.12B), while Visa Inc trades at $355.89 (market cap $680.35B). The key difference: Visa Inc is far larger — about 45× Davita Inc's market cap, and Visa Inc pays a 0.75% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | V | |
|---|---|---|
Market Cap | $15.12B | $680.35B |
Sector | Health | Financials |
52-Week High | $235.71 | $362.13 |
52-Week Low | $103.87 | $295.52 |
Enterprise Value | $27.67B | $690.94B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $357.75, up 2.52% today, with a bullish technical signal and strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue grew to $40.0 billion in 2025, and net income margin remains robust at 51.68%. The stock is near its pivot point of $357, with support at $354 and resistance at $360. Analysts maintain a strong buy consensus, with an average price target of $394.50.
The outlook for Visa is positive, driven by earnings momentum and strategic initiatives like AI-powered commerce tools. However, risks include competitive pressures from fintech and regulatory scrutiny. With 85% of analysts rating it a buy and institutional holdings increasing, the stock offers growth potential but requires monitoring of payment industry disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
